After announcing plans for a Rare Disease Innovation Hub this summer, the FDA has now taken key steps forward in establishing it — gathering feedback from partners in the rare disease community and creating a new senior leadership position.
The programme will act as a forum for the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER), enabling cross-centre collaboration across issues related to rare diseases.
Read more about The Hub and how it will help to identify new approaches to drug development and overcome some of the challenges associated with developing treatments for rare diseases.